All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Method of predicting the tumor response to DNA methylation inhibitors and alternative therapeutic regimens for overcoming resistance

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73586839" target="_blank" >RIV/61989592:15110/17:73586839 - isvavai.cz</a>

  • Result on the web

    <a href="https://data.epo.org/publication-server/pdf-document?pn=2924125&ki=B1&cc=EP" target="_blank" >https://data.epo.org/publication-server/pdf-document?pn=2924125&ki=B1&cc=EP</a>

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Method of predicting the tumor response to DNA methylation inhibitors and alternative therapeutic regimens for overcoming resistance

  • Original language description

    The present invention provides a method for predicting the sensitivity of a patient suffering from a cancer disease to DNA methylation inhibitor therapy, which comprises determining in vitro in cancer cells taken from the patient and comparing with values for parent type of cells - the level of expression of at least one bromodomain containing gene, and/or - the level of expression of at least one bromodomain containing protein and/or - the mutations involving the non-synonymous change in amino acid sequence of at least one bromodomain containing gene and/or - the half maximal inhibitory concentration (IC 50 ) of a DNA methylation inhibitor and/or a histone demethylase inhibitor, wherein the increase in the half maximal inhibitory concentration of the DNA methylation inhibitor and/or the histone demethylase inhibitor signifies cross-resistance, and/or - the half maximal inhibitory concentration (IC 50 ) of a selective BET bromodomain inhibitor, wherein the decrease in the half maximal inhibitory concentration of the selective BET bromodomain inhibitor signifies sensitivity. The invention further provides a combination therapy of cancers using bromodomain inhibitors in combination with DNA methylation inhibitors.

  • Czech name

  • Czech description

Classification

  • Type

    P - Patent

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

    <a href="/en/project/TE02000058" target="_blank" >TE02000058: Center of competence for molecular diagnostics and personalized medicine</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2017

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Patent/design ID

    EP 2924125

  • Publisher

    EPO_1 -

  • Publisher name

    European Patent Office

  • Place of publication

    Munich, The Hague, Berlin, Vienna, Brussels

  • Publication country

  • Date of acceptance

    Jun 14, 2017

  • Owner name

    Univerzita Palackého v Olomouci

  • Method of use

    A - Výsledek využívá pouze poskytovatel

  • Usage type

    A - K využití výsledku jiným subjektem je vždy nutné nabytí licence